Marshall Financial Group (Maryland)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Marshall Financial Group (Maryland)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,196	Closed	-$674K	–	187
2022 Q1	$674K	Sell	1,196 -30	-2%	-$18.1K	0.28%	134
2021 Q4	$926K	Buy	1,226 +158	+15%	+$118K	0.34%	107
2021 Q3	$797K	Buy	1,068 +74	+7%	+$55.4K	0.41%	84
2021 Q2	$640K	Buy	+994	New	+$605K	0.35%	107

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Financial Group (Maryland)'s BIO Position: Q2 2022 in Review

Marshall Financial Group (Maryland) sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 1,196 shares — an estimated $674K sold.

Marshall Financial Group (Maryland) first reported a position in BIO in Q2 2021 and held it in 4 quarters. The position peaked at $926K in Q4 2021. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

Marshall Financial Group (Maryland) reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
Marshall Financial Group (Maryland) sold 1,196 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $674K.
Marshall Financial Group (Maryland) first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and held it in 4 quarters.
Marshall Financial Group (Maryland)'s Bio-Rad Laboratories Class A position peaked at $926K in Q4 2021.
500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Marshall Financial Group (Maryland)'s 13F filing for Q2 2022, filed 25 Jul 2022.